EXP-561[1] is an investigational drug that acts as an inhibitor of the reuptake of serotonin, dopamine, and norepinephrine.

[2][3][4][5] It was developed in the 1960s by Du Pont[6] and was suggested as a potential antidepressant but failed in trials[7] and was never marketed.

[5][8][9][10] SAR simplification in the molecular structure leads to a compound called 4-Phenylcyclohexylamine [19992-45-1].

[12] Such compounds cause a desirable stimulation of the CNS and are antidepressants.

This drug article relating to the nervous system is a stub.